J. Safra Sarasin Holding AG Acquires 2,814 Shares of IQVIA Holdings Inc. $IQV

J. Safra Sarasin Holding AG raised its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 22.0% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,580 shares of the medical research company's stock after purchasing an additional 2,814 shares during the quarter. J. Safra Sarasin Holding AG's holdings in IQVIA were worth $2,455,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Clal Insurance Enterprises Holdings Ltd raised its position in IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock valued at $28,000 after purchasing an additional 131 shares during the last quarter. Golden State Wealth Management LLC raised its position in IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after purchasing an additional 130 shares during the last quarter. AllSquare Wealth Management LLC acquired a new stake in shares of IQVIA in the 1st quarter valued at $33,000. Larson Financial Group LLC increased its stake in shares of IQVIA by 109.9% in the 1st quarter. Larson Financial Group LLC now owns 275 shares of the medical research company's stock valued at $48,000 after buying an additional 144 shares during the period. Finally, Atticus Wealth Management LLC acquired a new stake in shares of IQVIA in the 2nd quarter valued at $52,000. Institutional investors own 89.62% of the company's stock.

Insider Transactions at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider directly owned 2,910 shares of the company's stock, valued at approximately $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

IQVIA Stock Up 1.2%

Shares of IQVIA stock opened at $206.84 on Friday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $237.34. The business has a fifty day simple moving average of $187.90 and a 200 day simple moving average of $167.69. The stock has a market cap of $35.16 billion, a PE ratio of 29.93, a price-to-earnings-growth ratio of 2.24 and a beta of 1.32.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same period in the previous year, the firm earned $2.64 earnings per share. The firm's quarterly revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on IQV shares. Robert W. Baird lifted their target price on IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a research note on Wednesday, July 23rd. Redburn Partners set a $214.00 target price on IQVIA in a research note on Wednesday, September 3rd. Cowen reissued a "buy" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Jefferies Financial Group raised IQVIA from a "hold" rating to a "buy" rating and lifted their target price for the company from $195.00 to $225.00 in a research note on Tuesday, September 9th. Finally, Truist Financial lifted their target price on IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Eighteen equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $230.32.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.